

BrainCool AB (publ): New order for 25 IQool™ System in the US

Update US market for IQool™ System

BrainCool has received an order for 25 IQool Systems from the company's distributor for the US market (ref 1), with an order value in the range of SEK 8-9 million.

In the reorganization effort our operations in the US, have 5 FTE left the company, furthermore our head of clinical support will join our distributors organization to work with our product October 1, 2023.

CEO Martin Waleij comments

- "We have had a very good start to the launch through a distributor and are now building a solid foundation for establishing the product as the market leader in the US."

Ref.

1. [ZOLL Expands Temperature Management Portfolio to Include IQool™ System, High-Quality Surface Option - ZOLL Medical](#)

Contacts

For more information

Martin Waleij - CEO

+46 - 733 -93 70 76

E-mail: martin.waleij@braincool.se

About Us

BrainCool AB (publ) is an innovative medical device company that develops, markets, and sells leading medical cooling systems for indications and areas with significant medical benefits within the healthcare sector. BrainCool AB (publ) is based in Lund, Sweden, and its share is listed on Nasdaq First North Growth Market, named "BRAIN".

Eminova Fondkommission AB is the company's Certified Adviser.

This information is information that BrainCool is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-08-30 08:40 CEST.

Attachments

[BrainCool AB \(publ\): New order for 25 IQool™ System in the US](#)